LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,485
تعداد دریافت فایل اصل مقاله11,291,272
parvaresh, R, Jalili, M, Haghparast, A, Khoshgard, K, Eivazi, M T, Ghorbani, M. (1399). Evaluations for Determination of Optimum Shields in Nuclear Medicine. سامانه مدیریت نشریات علمی, 10(5), 651-658. doi: 10.31661/jbpe.v0i0.1118
R parvaresh; M Jalili; A Haghparast; K Khoshgard; M T Eivazi; M Ghorbani. "Evaluations for Determination of Optimum Shields in Nuclear Medicine". سامانه مدیریت نشریات علمی, 10, 5, 1399, 651-658. doi: 10.31661/jbpe.v0i0.1118
parvaresh, R, Jalili, M, Haghparast, A, Khoshgard, K, Eivazi, M T, Ghorbani, M. (1399). 'Evaluations for Determination of Optimum Shields in Nuclear Medicine', سامانه مدیریت نشریات علمی, 10(5), pp. 651-658. doi: 10.31661/jbpe.v0i0.1118
parvaresh, R, Jalili, M, Haghparast, A, Khoshgard, K, Eivazi, M T, Ghorbani, M. Evaluations for Determination of Optimum Shields in Nuclear Medicine. سامانه مدیریت نشریات علمی, 1399; 10(5): 651-658. doi: 10.31661/jbpe.v0i0.1118

Evaluations for Determination of Optimum Shields in Nuclear Medicine

Journal of Biomedical Physics and Engineering
مقاله 15، دوره 10، شماره 5، دی 2020، صفحه 651-658    اصل مقاله (879.14 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.1118
نویسندگان
R parvaresh1؛ M Jalili* 2؛ A Haghparast3؛ K Khoshgard3؛ M T Eivazi3؛ M Ghorbani4
1MSc, Medical Physics Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
2MD, Nuclear Medicine Department, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
3PhD, Medical Physics Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
4PhD, Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Background: 131I source is widely used in the treatment of hyperthyroidism and thyroid cancers. 131I emits both beta and gamma-rays. Radiation protection is considered for gamma rays emitted by 131I. It seems no special shield against 131I source to be designed.
Objective: This research aims to evaluate determination of optimum shields in nuclear medicine against 99Tcm and 131I sources by dosimetric method. Additionally, Monte Carlo simulation was used to find the optimum thickness of lead for protection against 131I source.
Material and Methods: This is an experimental research in the field of radiation protection. A calibrated model of GraetzX5C Plus dosimeter was used to measure exposure rates passing through the shields. The efficiency of the shields was evaluated against 99Tcm and 131I. Furthermore, Monte Carlo simulation was used to find the optimum thickness of lead for protection against 131I source.
Results: The findings of the dosimetric method show that the minimum and maximum efficiencies obtained by the lead apron with lead equivalent thickness of 0.25 mm and the syringe holder shields with thickness of 0.5 mm lead were 50.86% and 99.50%, respectively. The results of the simulations show that the minimum and maximum efficiencies obtained by lead thicknesses of 1 mm and 43 mm were 19.36% and 99.79%, respectively.
Conclusion: The optimum shields against 99Tcm are the syringe holder shield, the tungsten syringe shield, and the lead partition, respectively. Furthermore, based on simulations, the thicknesses of 11-28 mm of lead with efficiencies between 90.6% to 99% are suggested as the optimum thicknesses to protect against 131I source.
کلیدواژه‌ها
Nuclear Medicine؛ Shield؛ Efficiency؛ Dosimetry؛ Monte Carlo Simulation؛ Iodine-131؛ 99Tcm
سایر فایل های مرتبط با مقاله
مراجع
  1. Fahey FH, Goodkind A, Treves ST, Grant FD. Nuclear medicine and radiation protection. J Radiol Nurs. 2016;35:5-11.
  2. Vucina J. Technetium-99m production for use in nuclear medicine. Med Pregl. 2000;53:631-4.
  3. Willegaignon J, Malvestiti LF, Guimaraes MI, Sapienza MT, Endo IS, Neto GC, et al. 131I effective half-life (Teff) for patients with thyroid cancer. Health Phys. 2006;91:119-22. doi: 10.1097/01.HP.0000202232.98823.87. PubMed PMID: 16832192.
  4. Bolus NE. Review of common occupational hazards and safety concerns for nuclear medicine technologists. J Nucl Med Technol. 2008;36:11-7. doi: 10.2967/jnmt.107.043869. PubMed PMID: 18287195.
  5. Oyar O, Kislalioglu A. How protective are the lead aprons we use against ionizing radiation? Diagn Interv Radiol. 2012;18:147-52. doi: 10.4261/1305-3825.DIR.4526-11.1. PubMed PMID: 22020951.
  6. Thompson MA. Radiation safety precautions in the management of the hospitalized (131)I therapy patient. J Nucl Med Technol. 2001;29:61-6. PubMed PMID: 11376097.
  7. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur. 2012;15:120-3. PubMed PMID: 22936505.
  8. Dokic DD. Technetium-99m radiopharmaceuticals for in vivo diagnostics. Med Pregl. 2005;58:180-4. doi: 10.2298/mpns0504180d. PubMed PMID: 16526218.
  9. Bushberg JT, Seibert JA, Leidholdt EM, Boone JM. The essential physics of medical imaging, 3rd Edition. North American: Lippincott Williams & Wilkins; 2011.
  10. Australian Radiation Protection and Nuclear Safety Agency. Safety guide radiation protection in nuclear medicine, No.14.2. [Accessed Feb 2017]. Available from: https://www.arpansa.gov.au/sites/default/files/legacy/pubs/rps/rps14_2.pdf.
  11. Radiation product design, Inc. Lead shielded syringe holder. 2017. [Accessed March 2017]. Available at: http://www.rpdinc.com/lead-shielded-syringe-holder-4485.html.
  12. Sylvain I, Bok B. Radiation exposure in nuclear medicine: real-time measurement. Braz Arch Biol Technol. 2002;45:111-4. doi: 1590/S1516-89132002000500015.
  13. Shultis JK, Faw RE. Mechanical and Nuclear Engineering, Kansas State University, Manhattan. [Accessed Nov. 2016]. Available at: http://www. bl831.als.lbl.gov/~mcfuser/publications/MCNP/MCNP.
  14. Parvaresh R, Haghparast A, Khoshgard K, Jalili M, Eivazi MT, Ghorbani M. An Investigation to Determine an Optimum Protective Garment Material in Nuclear Medicine. J Biomed Phys Eng. 2018;8:381-92. PubMed PMID: 30568928. PubMed PMCID: PMC6280121.
  15. Young AM. Dose rates in nuclear medicine and the effectiveness of lead aprons: updating the department’s knowledge on old and new procedures. Nucl Med Commun. 2013;34:254-64. doi: 10.1097/MNM.0b013e32835c91d5. PubMed PMID: 23353888.
  16. Ahmed S, Zimmer A, McDonald N, Spies S. The effectiveness of lead aprons in reducing radiation exposures from specific radionuclides. J Nucl Med. 2007;48:470P-P.
  17. Schürnbrand P, Schicha H, Thal H, Emrich D. External radiation exposure of personnel working with 99m Technetium. Eur J Nucl Med. 1982;7:237-9. doi: 10.1007/bf00256472.
  18. Smith B, Szyniszewski S, Hajjar J, Schafer B, Arwade S. Steel foam for structures: A review of applications, manufacturing and material properties. Journal of Constructional Steel Research. 2012;71:1-10. doi: 10.1016/j.jcsr.2011.10.028.
  19. Hubbell JH, Seltzer SM. X-ray mass attenuation coefficients. Standard reference data program of NIST. [Accessed May 2017]. Available from: http://physics.nist.gov/PhysRefData/XrayMassCoef/ElemTab/z82.html.
  20. Deb P, Jamison R, Mong L, U P. An evaluation of the shielding effectiveness of lead aprons used in clinics for protection against ionising radiation from novel radioisotopes. Radiation Protection Dosimetry. 2015;165:443-7. doi: 10.1093/rpd/ncv065.
آمار
تعداد مشاهده مقاله: 2,019
تعداد دریافت فایل اصل مقاله: 740


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب